FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer

被引:42
|
作者
Akita, H. [1 ]
Takahashi, H. [1 ]
Ohigashi, H. [2 ]
Tomokuni, A. [1 ]
Kobayashi, S. [1 ]
Sugimura, K. [1 ]
Miyoshi, N. [1 ]
Moon, J. -H. [1 ]
Yasui, M. [1 ]
Omori, T. [1 ]
Miyata, H. [1 ]
Ohue, M. [1 ]
Fujiwara, Y. [1 ]
Yano, M. [1 ]
Ishikawa, O. [1 ]
Sakon, M. [1 ]
机构
[1] Osaka Med Ctr Canc & Cardiovasc Dis OMCC, Dept Surg, Osaka, Japan
[2] Saiseikai Senri Hosp, Dept Surg, Suita, Osaka, Japan
来源
EJSO | 2017年 / 43卷 / 06期
关键词
Pancreatic cancer; Neoadjuvant; Chemoradiotherapy; FDG-PET; POSITRON-EMISSION-TOMOGRAPHY; GEMCITABINE-BASED CHEMORADIATION; PATHOLOGICAL RESPONSE; ADENOCARCINOMA; SURVIVAL; CHEMORADIOTHERAPY; CHEMOTHERAPY; RECURRENCE; PACLITAXEL; MANAGEMENT;
D O I
10.1016/j.ejso.2017.03.015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The efficacy of neoadjuvant chemoradiotherapy (NACRT) for resectable and borderline resectable pancreatic cancer is important for predicting outcomes after radical surgery, but few clinical indicators predict outcome before resection. This study examined the utility of FDG-PET in predicting the efficacy of NACRT and outcome after radical surgery. Methods: Eighty-three pancreatic cancer patients who underwent FDG-PET before and after NACRT and had positive standard uptake values (SUVs) before NACRT were enrolled in this study. Peri-operative clinical factors, including FDG-PET findings, were examined to predict the efficacy of NACRT and outcome after surgery. Results: Evans grade I, IIA, [03, III, and IV was determined in 11, 31, 27, 11, and 3 patients, respectively. The maximum SUVs after NACRT (post SUV-max) and tumor size were significantly decreased compared to pretreatment values (p < 0.001 and p = 0.007, respectively). The post SUV-max and regression index were significantly related to grade III/IV (p = 0.04 and p < 0.001, respectively), but only the regression index predicted NACRT efficacy (p = 0.002). The AUC of the regression index for the detection of grade III/IV was 0.822, and 13 of 14 grade lII/IV patients were picked up using 50% as the threshold (p < 0.001). Patients with a regression index >50% had a significantly better prognosis after radical resection than patients with <50% (p = 0.032). Regression index as well as pathological lymph node status and resectability status were independent prognostic factors in multivariate analysis (exp 2.086, p = 0.043). Conclusion: The regression index is potentially a good indicator of the efficacy of NACRT and outcome after radical resection for pancreatic cancer. (C) 2017 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
引用
收藏
页码:1061 / 1067
页数:7
相关论文
共 50 条
  • [31] Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer
    Schneider, Bryan J.
    Lee, Julia Shin-Jung
    Hayman, James A.
    Chang, Andrew C.
    Orringer, Mark B.
    Pickens, Allan
    Pan, Charlie C.
    Merajver, Sofia D.
    Urba, Susan G.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (02) : 435 - 442
  • [32] Metabolic activity by FDG-PET/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survival
    Lee, Woohyung
    Oh, Minyoung
    Kim, Jae Seung
    Park, Yejong
    Kwon, Jae Woo
    Jun, Eunsung
    Song, Ki Byung
    Lee, Jae Hoon
    Hwang, Dae Wook
    Yoo, Changhoon
    Kim, Kyu-Pyo
    Jeong, Jae Ho
    Chang, Heung-Moon
    Ryoo, Baek-Yeol
    Park, Seo Young
    Kim, Song Cheol
    BRITISH JOURNAL OF SURGERY, 2022, 109 (01) : 61 - 70
  • [33] Surgical Treatment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement by Evans et al.
    Adams, Reid B.
    Allen, Peter J.
    ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (07) : 1745 - 1750
  • [34] Preoperative MDCT Assessment of Resectability in Borderline Resectable Pancreatic Cancer: Effect of Neoadjuvant Chemoradiation Therapy
    Joo, Ijin
    Lee, Jeong Min
    Lee, Eun Sun
    Ahn, Su Joa
    Lee, Dong Ho
    Kim, Sun-Whe
    Ryu, Ji Kon
    Oh, Do-Youn
    Kim, Kyubo
    Lee, Kyoung-Bun
    Jang, Jin-Young
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2018, 210 (05) : 1059 - 1065
  • [35] Editorial Comment: FDG PET/MRI and CT as Predictive Markers of Response of Borderline Resectable Pancreatic Cancer to Neoadjuvant Therapy
    Lee, Jean H.
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2021, 217 (03) : 740 - 740
  • [36] The Application of Pre and Post Chemoradiation Therapy FDG-PET/CT to Treatment Strategy Selection in Locally Advanced Pancreatic Cancer
    Wilson, J. M.
    Mukherjee, S.
    Brunner, T. B.
    Partridge, M.
    Hawkins, M. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E130 - E131
  • [37] Preoperative Gemcitabine-based Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer Impact of Venous and Arterial Involvement Status on Surgical Outcome and Pattern of Recurrence
    Takahashi, Hidenori
    Akita, Hirofumi
    Tomokuni, Akira
    Kobayashi, Shogo
    Ohigashi, Hiroaki
    Fijiwara, Yoshiyuki
    Yano, Masahiko
    Sakon, Masato
    Ishikawa, Osamu
    ANNALS OF SURGERY, 2016, 264 (06) : 1091 - 1097
  • [38] Neoadjuvant Therapy Followed by Surgical Resection for Borderline Resectable Pancreatic Cancer With Artery Involvement
    Yamaue, Hiroki
    Hirono, Seiko
    Kawai, Manabu
    Okada, Ken-ichi
    Miyazawa, Motoki
    Shimizu, Atsushi
    Kitahata, Yuji
    GASTROENTEROLOGY, 2015, 148 (04) : S1164 - S1164
  • [39] Efficacy and feasibility of chemotherapy and radiation therapy for borderline resectable pancreatic cancer in elderly patients
    Figura, Nicholas
    Cruz, Alex
    Mellon, Eric Albert
    Chuong, Michael
    Hoffe, Sarah
    Springett, Gregory M.
    Saeed, Nadia
    Hodul, Pamela Joy
    Malafa, Mokenge Peter
    Balducci, Lodovico
    Shridhar, Ravi
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [40] The Role of Neoadjuvant Chemoradiation Therapy in Patients With Borderline Resectable Pancreatic Cancer With Isolated Venous Vascular Involvement
    Lee, Jin Ho
    Kang, Chang Moo
    Bang, Seung Min
    Choi, Jin Young
    Seong, Jin Sil
    Hwang, Ho Kyoung
    Choi, Sung Hoon
    Lee, Woo Jung
    MEDICINE, 2015, 94 (31)